Sex Differences in the Efficacy, Safety and Persistence of Patients with Psoriatic Arthritis Treated with Tofacitinib: A Post Hoc Analysis of Phase 3 Trials and Long-Term Extension
RMD Open 2023;9:e002718 doi 10.1136/rmdopen-2022-002718
Evidence from two phase 3 RCTs and one LTE shows that while tofacitinib efficacy exceeds placebo in both sexes and is comparable between sexes, males are more likely to achieve minimal disease activity than females.
Previous trials have demonstrated females respond worse than males to PsA therapy. However, the impact of sex on the efficacy, safety and persistence of tofacitinib treatment in patients with PsA has not previously been reported. To address this, Eder, et al. evaluated the impact of sex on tofacitinib therapy in this post hoc analysis.